Puridify establishes Scientific Advisory Board

London, UK - 07 March 2016 - Puridify Limited ("Puridify"), developers of novel bioprocessing purification technologies for industrial biomolecule manufacture, today announced the establishment of a Scientific Advisory Board (SAB). The SAB comprises world-renowned key opinion leaders in the field of biotherapeutic manufacturing, with a wealth of experience covering both the academic and industrial setting.

The SAB comprises the following members:

- Dr Daniel Bracewell
- Dr Barry Buckland
- Dr Karol Lacki
- Dr Will Lewis
- Dr John Liddell

Further biographical details on the members of the SAB are given below.

The SAB members have extensive experience in the development and application of truly novel approaches to downstream processing to multiple biotherapeutic modalities. Puridify will seek their guidance relating to the development of its proprietary nanofibre purification platform, FibroSelect.

Commenting on the formation of the Scientific Advisory Board, Oliver Hardick CEO, said:
"We are very pleased to have the support of such a distinguished mix of individuals whose input from their complementary backgrounds will help accelerate the commercialisation of our single-use purification technology."

Biographical details of the SAB members:

Dr Daniel G. Bracewell
Daniel is a Reader in Bioprocess Analysis at the UCL Department of Biochemical Engineering. He has made major contributions to the fundamental understanding of biopharmaceutical purification operations, generating over £5.5 million in research funds including new international research collaborations with India and the USA. He has authored more than 70 peer reviewed journal articles in the area to date and currently supervises 15 doctoral and postdoctoral projects, many of these studies are in collaboration with industry. A previous research project is the basis for the technology from which Puridify has developed.

Prof Barry Buckland
Barry has obtained a PhD in Biochemical Engineering at University College London in 1974. He joined the Merck Research Laboratories (MRL) in 1980 and built a world class Bioprocess R&D group leading process development of all biologically made product candidates within the MRL pipeline and the manufacture of Clinical Supplies during a 20 year time frame. Products developed within this period include MEVACOR®, ZOCOR®, IVOMEC®, CANCIDAS®, RECOMBIVAX HB®, VAQTA®, VARIVAX®, COMVAX®., ROTATEQ® (Rotavirus vaccine), ZOSTAVAX® (shingles vaccine) and GARDASIL® (HPV vaccine). External awards and appointments include being elected to the National Academy of

Engineering in 1997 and Fellow of University College London in 1998. Awards include the Donald Medal, UK Institute of Chemical Engineering in 2002, Prix Galien award: Member of team to receive Vaccine Award for Gardasil® in 2007, Merck Board of Directors Award for leading process development for licensure of four (4) new vaccines in 2007. Chaired two International Conferences on Cell Culture (Cell Culture Engineering IV and Cell Culture Engineering V) and co-chaired the first four International Conferences on Vaccine Technology. Barry started BiologicB in 2009 to provide consultancy worldwide to a number of companies and not-for-profit institutions, in all areas of Biologics including Vaccines and Therapeutic Proteins. He also sits on the Board of directors for a number of organisations.

Dr Karol Łącki

Karol Łącki received his Bachelor and later Master in Applied Science degree in Process and Chemical Engineering from the Warsaw Technical University, Poland, and his Ph.D. degree in Chemical Engineering from the University of Ottawa, Canada. In his previous roles Karol has lead the Mathematical Modelling department at Novo Nordisk, Denmark. Before that, he had spent 17 years working for GE Healthcare R&D in Uppsala, Sweden, conducting research pertaining to development of chromatography resin, modeling and optimization of separation processes. His research also included development of high throughput methods for designing and characterization of chromatographic separations, and development of continuous chromatography concept. In his role as staff scientist he provided scientific support to various research and development projects in areas related to process engineering and chromatography media development. He was also responsible for GE Healthcare R&D customer collaborations. His research interests and expertise include new approaches to process intensification, mechanistic modeling and optimization of downstream processes, and new approaches to process development and characterisation. Karol has published papers and book chapters in the field of process biotechnology. He has participated in numerous scientific meetings, and has co-chaired several sessions/workshops at major biotechnology conferences, including Recovery of Biological Products conference series. He also serves on advisory boards of some of those. He co-chaired the 2nd Integrated Continuous Bioprocessing conference. He is a co-founder of and a co-chair of a non-profit High Throughput Process Development conference series.

Dr Will Lewis

Will gained an EngD in Bioprocessing looking at the manufacture of camelid antibody fragments at University College London sponsored by Unilever. After completion of this project Will then returned to work for Unilever for 2 years further exploring the manufacture and use of a number of novel proteins in a biotechnology setting. In 2008 he then moved to GSK in Stevenage developing processes to purify domain antibodies in preparation for clinical manufacture, then expanding into other formats including mAbs, novel mAb-like proteins and recombinant proteins. During this time he progressed to principal scientist and then moved on to lead the downstream process research group for the last 2 years. The group specialises in de-risking the downstream processing of new biopharm molecules and accelerating them into early clinical manufacture in conjunction with wider functions in cell line development, upstream, analytical and formulation.

Dr John Liddell

John most recently held senior bioprocessing development positions with Fujifilm Diosynth Biotechnologies developing and applying innovative solutions for a diverse range of biotherapeutic proteins for the company's international client base. Prior to Fujifilm he held senior bioprocessing development roles in ICI, Zeneca, Avecia and Merck. He has almost 30 years' experience in bioprocess development with broadly based experience covering recovery of biopharmaceutical products from both microbial and mammalian cell expression systems. Bioprocessing experience has covered a very diverse range of biopharmaceutical proteins and other molecules as well as earlier IBB experience. He has been directly involved in all phases of bioprocess development from

preclinical and early phase process definition through to late phase process and product characterisation as well as process validation. He has been responsible for implementation and development of innovative process technologies originated in house and through external collaborative programmes. He is a named inventor on a number of bioprocess patents.

END

About Puridify Ltd

Puridify Limited is a UK-based bioprocessing company formed in 2013. Puridify's platform purification technology, FibroSelect, aims to address the demands of the bioprocessing industry through enabling new processing strategies. The company is privately funded by leading venture capital investors Imperial Innovations and SR One, with additional support from UCL Business. Puridify's head office and research & development facilities are based at the Stevenage Bioscience Catalyst, 20 minutes north of London.

For more information, visit www.puridify.com

For more information, please contact:
Dr Oliver Hardick, Chief Executive Officer
Puridify Ltd
E: info@puridify.com